دورية أكاديمية
أعرض في EDS

Congress of Neurological Surgeons Systematic Review and Evidence-Based Guidelines on the Management of Progressive Glioblastoma in Adults: Update of the 2014 Guidelines.

التفاصيل البيبلوغرافية
العنوان: Congress of Neurological Surgeons Systematic Review and Evidence-Based Guidelines on the Management of Progressive Glioblastoma in Adults: Update of the 2014 Guidelines.
المؤلفون: Germano IM; Department of Neurosurgery, Icahn School of Medicine at Mount Sinai, New York, New York, USA., Johnson DR; Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA., Patrick HH; Department of Neurological Surgery, George Washington University, Washington, District of Columbia, USA., Goodman AL; Department of Pathology and Laboratory Medicine, Emory University Hospital, Atlanta, Georgia, USA., Ziu M; Department of Neurosurgery, Inova Neuroscience and Spine Institute Fairfax, Virginia, USA., Ormond DR; Department of Neurosurgery, University of Colorado School of Medicine, Aurora, Colorado, USA., Olson JJ; Department of Neurosurgery, Emory University School of Medicine, Atlanta, Georgia, USA.
المصدر: Neurosurgery [Neurosurgery] 2022 May 01; Vol. 90 (5), pp. e112-e115.
نوع المنشور: Journal Article; Practice Guideline; Research Support, Non-U.S. Gov't; Systematic Review
اللغة: English
بيانات الدورية: Publisher: Lippincott Williams & Wilkins, Inc Country of Publication: United States NLM ID: 7802914 Publication Model: Print Cited Medium: Internet ISSN: 1524-4040 (Electronic) Linking ISSN: 0148396X NLM ISO Abbreviation: Neurosurgery Subsets: MEDLINE
أسماء مطبوعة: Publication: 2022- : [Philadelphia] : Lippincott Williams & Wilkins, Inc.
Original Publication: Baltimore, Williams & Wilkins.
مواضيع طبية MeSH: Glioblastoma*/diagnosis , Glioblastoma*/therapy , Neurosurgeons*, Adult ; Humans
مستخلص: Background: The Institute of Medicine best practice recommendation to review guidelines every 5 years is followed by the Congress of Neurological Surgeons Guidelines Committee. The aim of this work was to provide an updated literature review and evidence-based recommendations on the topic of diagnosis and treatment of patients with progressive glioblastoma (pGBM).
Objective: To review the literature published since the last guidelines on pGBM dated 2014, with literature search ending in June 2012.
Methods: PubMed, Embase, and Cochrane were searched for the period July 1, 2012, to March 31, 2019, using search terms and search strategies to identify pertinent abstracts. These were then screened using published exclusion/inclusion criteria to identify full-text review articles. Evidence tables were constructed using data derived from full-text reviews and recommendations made from the evidence derived.
Results: From the total 8786 abstracts identified by the search, 237 full-text articles met inclusion/exclusion criteria and were included in this update. Two new level II recommendations derived from this work. For the diagnosis of patients with GBM, the use of diffusion-weighted images is recommended to be included in the magnetic resonance images with and without contrast used for surveillance to detect pGBM. For the treatment of patients with pGBM, repeat cytoreductive surgery is recommended to improve overall survival. An additional 21 level III recommendations were provided.
Conclusion: Recent published literature provides new recommendations for the diagnosis and treatment of pGBM. The Central Nervous System Guidelines Committee will continue to pursue timely updates to further improve the care of patients with diagnosis.https://www.cns.org/guidelines/browse-guidelines-detail/guidelines-management-of-progressive-glioblastoma.
(Copyright © Congress of Neurological Surgeons 2022. All rights reserved.)
References: (US) Committee on Standards for Developing Trustworthy Clinical Practice Guidelines. Clinical Practice Guidelines We Can Trust. Institute of Medicine, National Academies Press; 2000.
Olson JJ, Ryken TC, Kalkanis SN. The management of progressive glioblastoma: a systematic review and evidence-based clinical practice guideline: introduction and rationale. J Neurooncol. 2014;118(3):435-460.
Ryken TC, Aygun N, Morris J, et al. The role of imaging in the management of progressive glioblastoma. J Neurooncol. 2014;118(3):435-460.
Ellingson BM, Kim E, Woodworth DC, et al. Diffusion MRI quality control and functional diffusion map results in ACRIN 6677/RTOG 0625: a multicenter, randomized, phase II trial of bevacizumab and chemotherapy in recurrent glioblastoma. Int J Oncol. 2015;46(5):1883-1892.
Ellingson BM, Gerstner ER, Smits M, et al. Diffusion MRI phenotypes predict overall survival benefit from anti-VEGF monotherapy in recurrent glioblastoma: converging evidence from phase II trials. Clin Cancer Res. 2017;23(19):5745-5756.
Ryken TC, Kalkanis SN, Buatti JM, Olson JJ. The role of cytoreductive surgery in the management of progressive glioblastoma. J Neurooncol. 2014;118(3):479-488.
Yong RL, Wu T, Mihatov N, et al. Residual tumor volume and patient survival following reoperation for recurrent glioblastoma. J Neurosurg. 2014;121(4):802-809.
Suchorska B, Weller M, Tabatabai G, et al. Complete resection of contrast-enhancing tumor volume is associated with improved survival in recurrent glioblastoma-results from the DIRECTOR trial. Neurooncology. 2016;18(4):549-556.
D'Amico RS, Cloney MB, Sonabend AM, et al. The safety of surgery in elderly patients with primary and recurrent glioblastoma. World Neurosurg. 2015;84(4):913-919.
Hager J, Herrmann E, Kammerer S, et al. Impact of resection on overall survival of recurrent Glioblastoma in elderly patients. Clin Neurol Neurosurg. 2018;174:21-25.
Brat DJ, Ryken TC, Kalkanis SN, Olson JJ. The role of neuropathology in the management of progressive glioblastoma: a systematic review and evidence-based clinical practice guideline. J Neurooncol. 2014;118(3):461-478.
Louis D, Ohgaki H, Wiestler O, WK C. World Health Organization Histological Classification of Tumours of the Central Nervous System. Vol 1. Revised 4th ed. International Agency for Research on Cancer; 2016.
Liu B, Pang B, Liu H, et al. High mobility group A1 expression shows negative correlation with recurrence time in patients with glioblastoma multiforme. Pathol Res Pract. 2015;211(8):596-600.
Okita Y, Narita Y, Miyakita Y, et al. Pathological findings and prognostic factors in recurrent glioblastomas. Brain Tumor Pathol. 2012;29(4):192-200.
Brandes AA, Franceschi E, Paccapelo A, et al. Role of MGMT methylation status at time of diagnosis and recurrence for patients with glioblastoma: clinical implications. Oncologist. 2017;22(4):432-437.
Reardon DA, Omuro A, Brandes AA, et al. OS10.3 randomized phase 3 study evaluating the efficacy and safety of nivolumab vs bevacizumab in patients with recurrent glioblastoma: CheckMate 143. Neurooncology. 2017;19(suppl 3):iii21-iii22.
Indraccolo S, Lombardi G, Fassan M, et al. Genetic, epigenetic, and immunologic profiling of MMR-deficient relapsed glioblastoma. Clin Cancer Res. 2019;25(6):1828-1837.
Cioca A, Olteanu EG, Gisca MD, Morosanu CO, Marin I, Florian IS. Expression of EGFR in paired new and recurrent glioblastomas. Asian Pac J Cancer Prev. 2016;17(9):4205-4208.
Byron SA, Tran NL, Halperin RF, et al. Prospective feasibility trial for genomics-informed treatment in recurrent and progressive glioblastoma. Clin Cancer Res. 2018;24(2):295-305.
Neilsen BK, Sleightholm R, McComb R, et al. Comprehensive genetic alteration profiling in primary and recurrent glioblastoma. J Neurooncol. 2019;142(1):111-118.
Cimino PJ, McFerrin L, Wirsching HG, et al. Copy number profiling across glioblastoma populations has implications for clinical trial design. Neurooncology. 2018;20(10):1368-1373.
Olson JJ, Nayak L, Ormond DR, Wen PY, Kalkanis SN. The role of cytotoxic chemotherapy in the management of progressive glioblastoma: a systematic review and evidence-based clinical practice guideline. J Neurooncol. 2014;118(3):501-555.
Lu G, Rao M, Zhu P, et al. Triple-drug therapy with bevacizumab, irinotecan, and temozolomide plus tumor treating fields for recurrent glioblastoma: a retrospective study. Front Neurol. 2019;10:42.
Kesari S, Ram Z. Tumor-treating fields plus chemotherapy versus chemotherapy alone for glioblastoma at first recurrence: a post hoc analysis of the EF-14 trial. CNS Oncol. 2017;6(3):185-193.
Ansstas G, Tran DD. Treatment with tumor-treating fields therapy and pulse dose bevacizumab in patients with bevacizumab-refractory recurrent glioblastoma: a case series. Case Rep Neurol. 2016;8(1):1-9.
Wong ET, Lok E, Swanson KD. Clinical benefit in recurrent glioblastoma from adjuvant NovoTTF-100A and TCCC after temozolomide and bevacizumab failure: a preliminary observation. Cancer Med. 2015;4(3):383-391.
Rulseh AM, Keller J, Klener J, et al. Long-term survival of patients suffering from glioblastoma multiforme treated with tumor-treating fields. World J Surg Oncol. 2012;10(1):220.
Stupp R, Wong ET, Kanner AA, et al. NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. Eur J Cancer. 2012;48(14):2192-2202.
Lang FF, Conrad C, Gomez-Manzano C, et al. Phase I study of DNX-2401 (Delta-24-RGD) oncolytic adenovirus: replication and immunotherapeutic effects in recurrent malignant glioma. J Clin Oncol. 2018;36(14):1419-1427.
Geletneky K, Hajda J, Angelova AL, et al. Oncolytic H-1 parvovirus shows safety and signs of immunogenic activity in a first phase I/IIa glioblastoma trial. Mol Ther. 2017;25(12):2620-2634.
Cloughesy TF, Landolfl J, Hogan DJ, et al. Vogelbaum MA phase 1 trial of vocimagene amiretrorepvec and 5-fluorocytosine for recurrent high-grade glioma. Sci Transl Med. 2016;8(341):341ra375.
Kicielinski KP, Chiocca EA, Yu JS, Gill GM, Coffey M, Markert JM. Phase 1 clinical trial of intratumoral reovirus infusion for the treatment of recurrent malignant gliomas in adults. Mol Ther. 2014;22(5):1056-1062.
Markert JM, Liechty PG, Wang W, et al. Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM. Mol Ther. 2009;17(1):199-207.
Forsyth P, Roldán G, George D, et al. A phase I trial of intratumoral administration of reovirus in patients with histologically confirmed recurrent malignant gliomas. Mol Ther. 2008;16(3):627-632.
Freeman AI, Zakay-Rones Z, Gomori JM, et al. Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme. Mol Ther. 2006;13(1):221-228.
Chiocca EA, Abbed KM, Tatter S, et al. A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting. Mol Ther. 2004;10(5):958-966.
Cloughesy TF, Petrecca K, Walbert T, et al. Effect of vocimagene amiretrorepvec in combination with flucytosine vs standard of care on survival following tumor resection in patients with recurrent high-grade glioma: a randomized clinical trial. JAMA. 2020;6(12):1939-1946.
Brem H, Piantadosi S, Burger PC, et al. Placebo-controlled trial of safety and efficacy of intra-operative controlled biodegradable polymers of chemotherapy for recurrent gliomas. Lancet Oncol. 1995;365(8956):1008-1012.
Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in a randomized phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10(5):459-466.
Ryu S, Buatti JM, Morris A, Kalkanis SN, Ryken TC, Olson JJ. The role of radiotherapy in the management of progressive glioblastoma: a systematic review and evidence-based clinical practice guideline. J Neurooncol. 2014;118(3):489-499.
Greenspoon JN, Sharieff W, Hirte H, et al. Fractionated stereotactic radiosurgery with concurrent temozolomide chemotherapy for locally recurrent glioblastoma multiforme: a prospective cohort study. OncoTargets Ther. 2014;7:485-490.
Pinzi V, Orsi C, Marchetti M, et al. Radiosurgery reirradiation for high-grade glioma recurrence: a retrospective analysis. Neurol Sci. 2015;36(8):1431-1440.
Straube C, Elpula G, Gempt J, et al. Re-irradiation after gross total resection of recurrent glioblastoma: spatial pattern of recurrence and a review of the literature as a basis for target volume definition. Strahlenther Onkol. 2017;193(11):897-909.
Straube C, Antoni S, Gempt J, et al. Re-irradiation in elderly patients with glioblastoma: a single institution experience. J Neurooncol. 2019;142(2):327-335.
Brautigam E, Lampl C, Track C, et al. Re-irradiation of recurrent glioblastoma as part of a sequential multimodality treatment concept. Clin Transl Oncol. 2019;21(5):582-587.
Hasan S, Chen E, Lanciano R, et al. Salvage fractionated stereotactic radiotherapy with or without chemotherapy and immunotherapy for recurrent glioblastoma multiforme: a single institution experience. Front Oncol. 2015;5:106.
Ciammella P, Podgornii A, Galeandro M, et al. Hypofractionated stereotactic radiation therapy for recurrent glioblastoma: single institutional experience. Radiat Oncol. 2013;8(1):222.
Zwirner K, Paulsen F, Schittenhelm J, et al. Prognostic parameters and outcome after re-irradiation for progressive glioblastoma. Acta Neurol Scand. 2017;136(3):239-245.
Yazici G, Cengiz M, Ozyigit G, et al. Hypofractionated stereotactic reirradiation for recurrent glioblastoma. J Neurooncol. 2014;120(1):117-123.
Olson JJ, Nayak L, Ormond DR, Wen PY, Kalkanis SN, Ryken TC. The role of targeted therapies in the management of progressive glioblastoma: a systematic review and evidence-based clinical practice guideline. J Neurooncol. 2014;118(3):557-599.
Cai LB, Li J, Lai MY, et al. Bevacizumab rescue therapy extends the survival in patients with recurrent malignant glioma. Chin J Cancer Res. 2013;25(2):206-211.
Flieger M, Ganswindt U, Schwarz SB, et al. Re-irradiation and bevacizumab in recurrent high-grade glioma: an effective treatment option. J Neurooncol. 2014;117(2):337-345.
Kaloshi G, Brace G, Rroji A, et al. Bevacizumab alone at 5 mg/kg in an every-3-week schedule for patients with recurrent glioblastomas: a single center experience. Tumori. 2013;99(5):601-603.
Nagane M, Nishikawa R, Narita Y, et al. Phase II study of single-agent bevacizumab in Japanese patients with recurrent malignant glioma. Jpn J Clin Oncol. 2012;42(10):887-895.
تواريخ الأحداث: Date Created: 20220415 Date Completed: 20230817 Latest Revision: 20231011
رمز التحديث: 20231012
DOI: 10.1227/neu.0000000000001903
PMID: 35426875
قاعدة البيانات: MEDLINE
الوصف
تدمد:1524-4040
DOI:10.1227/neu.0000000000001903